Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
作者
BRUCE H. THIERS
出处
期刊:Yearbook of Dermatology and Dermatologic Surgery日期:2009-01-01卷期号:2009: 146-148